BR112022010871A2 - Composições farmacêuticas oftalmológicas - Google Patents
Composições farmacêuticas oftalmológicasInfo
- Publication number
- BR112022010871A2 BR112022010871A2 BR112022010871A BR112022010871A BR112022010871A2 BR 112022010871 A2 BR112022010871 A2 BR 112022010871A2 BR 112022010871 A BR112022010871 A BR 112022010871A BR 112022010871 A BR112022010871 A BR 112022010871A BR 112022010871 A2 BR112022010871 A2 BR 112022010871A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- ophthalmological pharmaceutical
- ophthalmological
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944074P | 2019-12-05 | 2019-12-05 | |
| US202063077196P | 2020-09-11 | 2020-09-11 | |
| PCT/US2020/063218 WO2021113580A1 (en) | 2019-12-05 | 2020-12-04 | Ophthalmic pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010871A2 true BR112022010871A2 (pt) | 2022-08-23 |
Family
ID=74104179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010871A BR112022010871A2 (pt) | 2019-12-05 | 2020-12-04 | Composições farmacêuticas oftalmológicas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230026577A1 (https=) |
| EP (1) | EP4069195A1 (https=) |
| JP (2) | JP7833399B2 (https=) |
| KR (1) | KR20220128619A (https=) |
| CN (1) | CN115397392A (https=) |
| AU (1) | AU2020398224B2 (https=) |
| BR (1) | BR112022010871A2 (https=) |
| CA (1) | CA3160484A1 (https=) |
| CL (1) | CL2022001463A1 (https=) |
| CO (1) | CO2022009260A2 (https=) |
| IL (1) | IL293541A (https=) |
| MX (1) | MX2022006776A (https=) |
| TW (1) | TWI845795B (https=) |
| WO (1) | WO2021113580A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300628A (en) * | 2020-09-10 | 2023-04-01 | Vanda Pharmaceuticals Inc | Methods for the treatment of cyclic diseases or conditions-PDE IV |
| HU231668B1 (hu) * | 2021-12-28 | 2025-06-28 | Semmelweis Egyetem 60% | Szemcsepp készítmény |
| US20250073125A1 (en) * | 2023-09-06 | 2025-03-06 | Opus Life Sciences, Llc | High ph formulations and kits |
| WO2025179141A1 (en) | 2024-02-22 | 2025-08-28 | Vanda Pharmaceuticals, Inc. | Treatment of dry eye disease |
| KR20260048121A (ko) * | 2024-10-02 | 2026-04-09 | 주식회사 대웅테라퓨틱스 | 개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1321144T3 (da) * | 2000-09-13 | 2011-03-07 | Santen Pharmaceutical Co Ltd | Øjendråber |
| CN101537172B (zh) | 2008-08-14 | 2010-06-30 | 温州医学院 | 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 |
| CN101690712B (zh) | 2009-08-25 | 2011-06-15 | 武汉武药科技有限公司 | 一种西他沙星滴眼剂及其制备方法 |
| US20110178147A1 (en) | 2009-10-20 | 2011-07-21 | Allergan, Inc. | Compositions and methods for controlling pupil dilation |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| CN102988280B (zh) | 2012-10-08 | 2014-03-19 | 新乡医学院 | 一种加雷沙星滴眼剂 |
| CN109481392B (zh) * | 2015-09-02 | 2021-12-24 | 盛世泰科生物医药技术(苏州)有限公司 | 一种用于预防和治疗白内障的眼用制剂及其制备方法 |
| WO2017083799A1 (en) * | 2015-11-13 | 2017-05-18 | Ohr Pharmaceutical, Inc. | Ophthalmic formulations of squalamine |
| MX383072B (es) * | 2015-12-24 | 2025-03-13 | Univ California | Reguladores del cftr y métodos para su uso |
| US20180236077A1 (en) | 2017-02-21 | 2018-08-23 | Avedro, Inc. | Formulations for eye treatments |
| JP2020531511A (ja) | 2017-08-24 | 2020-11-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 眼球用医薬組成物 |
-
2020
- 2020-12-04 BR BR112022010871A patent/BR112022010871A2/pt unknown
- 2020-12-04 JP JP2022533510A patent/JP7833399B2/ja active Active
- 2020-12-04 CN CN202080094414.9A patent/CN115397392A/zh active Pending
- 2020-12-04 AU AU2020398224A patent/AU2020398224B2/en active Active
- 2020-12-04 KR KR1020227022823A patent/KR20220128619A/ko active Pending
- 2020-12-04 EP EP20830416.2A patent/EP4069195A1/en active Pending
- 2020-12-04 US US17/782,197 patent/US20230026577A1/en active Pending
- 2020-12-04 IL IL293541A patent/IL293541A/en unknown
- 2020-12-04 MX MX2022006776A patent/MX2022006776A/es unknown
- 2020-12-04 CA CA3160484A patent/CA3160484A1/en active Pending
- 2020-12-04 WO PCT/US2020/063218 patent/WO2021113580A1/en not_active Ceased
- 2020-12-04 TW TW109142969A patent/TWI845795B/zh active
-
2022
- 2022-06-02 CL CL2022001463A patent/CL2022001463A1/es unknown
- 2022-07-01 CO CONC2022/0009260A patent/CO2022009260A2/es unknown
-
2025
- 2025-07-14 JP JP2025117830A patent/JP2025160247A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220128619A (ko) | 2022-09-21 |
| TWI845795B (zh) | 2024-06-21 |
| AU2020398224A1 (en) | 2022-06-30 |
| AU2020398224B2 (en) | 2026-02-19 |
| JP7833399B2 (ja) | 2026-03-19 |
| JP2025160247A (ja) | 2025-10-22 |
| WO2021113580A1 (en) | 2021-06-10 |
| CA3160484A1 (en) | 2021-06-10 |
| CN115397392A (zh) | 2022-11-25 |
| CO2022009260A2 (es) | 2022-09-20 |
| JP2023505255A (ja) | 2023-02-08 |
| TW202128178A (zh) | 2021-08-01 |
| EP4069195A1 (en) | 2022-10-12 |
| MX2022006776A (es) | 2022-09-19 |
| IL293541A (en) | 2022-08-01 |
| US20230026577A1 (en) | 2023-01-26 |
| CL2022001463A1 (es) | 2023-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010871A2 (pt) | Composições farmacêuticas oftalmológicas | |
| ECSP21088515A (es) | Compuestos de pirrolidina | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CR20200312A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2018003130A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX391414B (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| BR112016024235A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| MX373603B (es) | Activador de canales de kcnq2-5. | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| WO2016068580A3 (en) | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| MX2021015873A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024022133-0 PROTOCOLO 870240091064 EM 24/10/2024 16:07. |